| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1023880af10dbe26a57dfb1cb687f92d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a61fdd882b0f725ab16e8fef9005324f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate |
2006-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63f717d7ad0cc7f4427a6d6be4b8bfa0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0882bd000d547dcc5e46d53aac6f90a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0391c2a5f93404df9fe2b8a5f3137137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6e779979b374379c1a14c4f1878c0bd |
| publicationDate |
2010-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-PI0609614-A2 |
| titleOfInvention |
use of ezetimibe in the prevention and treatment of biliary tree cholesterol lithiases |
| abstract |
USE OF EZETIMIBA IN PREVENTION AND TREATMENT OF CHOLESTEROL LYTIASIS IN THE BILARY TREE. This invention discloses the use of compounds of the azetidinone family in the prevention or treatment of biliary tree cholesterol disease in mammals. This invention is included in the general field of gallstone disease of the gallbladder and gallbladder. In particular, the invention provides evidence that the use of drugs that specifically block intestinal cholesterol absorption inhibits the onset of cholesterol biliary tree disease. These drugs act by decreasing bile cholesterol secretion and at the same time increasing bile flow and liver secretion of endogenous compounds (eg bile salts, phospholipids) in the bile. In turn, these endogenous compounds contribute to inhibit the precipitation of cholesterol and the formation of lithiasis in the biliary tree. |
| priorityDate |
2005-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |